25 June 2018
Together with the ERN GENTURIS, they will set-up a large European PHTS cohort to pave the way for more personalised cancer risk management and treatment.
UK PTEN Research Foundation: link.
Janet Vos (photo), Nicoline Hoogerbrugge and Marleen Kets, theme Tumors of the digestive tract, received € 265.000 funding from the UK PTEN Research Foundation.
Together with the ERN GENTURIS, they will set-up a large European PHTS cohort to pave the way for more personalised cancer risk management and treatment.
UK PTEN Research Foundation: link.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items

Renee Salz wins prize for best presentation
10 May 2022 Renee Salz won the award for best oral presentation during the Rolduc genetics retreat, organized by the Dutch and Belgian Societies of Human Genetics in Brugge. Her presentation was titled "Variant effect prediction based on long read transcriptomes". read more
What can we learn from rural Tanzanian food?
23 December 2021 What we eat affects our bodies. A diet high in plant based products and low in fat offers health benefits and prevents lifestyle diseases, such as cardiovascular disease. This is what Quirijn de Mast shows based on his research in Africa. read more
Awarded KWF grants for Radboudumc researchers
18 December 2019 KWF is investing 2.7 million euros in five different studies at Radboudumc. The awards are part of the new round of funding by DCS, in which over 34 million euros will be granted to Dutch cancer research. We congratulate our researchers with this funding and wish them success with their great work. read more
Nicoline Hoogerbrugge and Michiel Vermeulen newly elected in Academia Europaea
26 July 2019 The Academia Europaea is a functioning European Academy of Humanities, Letters and Sciences, composed of individual members. read more
Universal tumor BRCA1/2 testing of ovarian cancer
13 May 2019 Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI. read more